| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
783 |
536 |
$109K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
896 |
671 |
$79K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
365 |
130 |
$76K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
513 |
507 |
$69K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
549 |
427 |
$23K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
403 |
398 |
$14K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
162 |
158 |
$13K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
50 |
17 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
262 |
160 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
92 |
42 |
$2K |